Tags

Type your tag names separated by a space and hit enter

Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
Expert Opin Pharmacother. 2015; 16(10):1449-61.EO

Abstract

INTRODUCTION

The prevalence of chronic kidney disease (CKD), a risk factor for cardiovascular disease (CVD), is increasing worldwide. Statin treatment, the cornerstone of prevention or treatment of CVD, might have beneficial effects on urine protein excretion and renal function as determined by the glomerular filtration rate, whereas it might protect from acute kidney injury (AKI), mainly due to contrast-induced AKI. These beneficial effects on CKD may not be drug class effects; specific statins at specific doses may help prevent CKD deterioration and reduce CVD risk. We analysed all statin studies that had renal and CVD endpoints as main outcome measures. MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched up to February 2015.

AREAS COVERED

We consider the effects of statins on microalbuminuria, proteinuria, glomerular filtration rate, AKI associated with angiography or percutaneous coronary intervention and on CVD event rates in patients with CKD.

EXPERT OPINION

Current evidence points towards the need to prescribe high-potency statins in patients with CKD, before a major decline in kidney function occurs. This may reduce CVD risk and delay the progress of CKD. Administration of either atorvastatin or rosuvastatin can prevent contrast-induced AKI before angiography or percutaneous coronary intervention. The combination of simvastatin + ezetimibe may decrease vascular events in patients with advanced CKD.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Athyros VG
Aristotle University of Thessaloniki, Hippocration Hospital, Medical School, Second Propedeutic Department of Internal Medicine , Thessaloniki , Greece +30 2310 892606 ; +30 2310 835955 ; vathyros@gmail.com.
Katsiki N
No affiliation info available
Karagiannis A
No affiliation info available
Mikhailidis DP
No affiliation info available

MeSH

Acute Kidney InjuryAtorvastatinCardiovascular DiseasesGlomerular Filtration RateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKidney Failure, ChronicRenal Insufficiency, ChronicRiskRosuvastatin CalciumSimvastatin

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26037614

Citation

Athyros, Vasilios G., et al. "Statins Can Improve Proteinuria and Glomerular Filtration Rate Loss in Chronic Kidney Disease Patients, Further Reducing Cardiovascular Risk. Fact or Fiction?" Expert Opinion On Pharmacotherapy, vol. 16, no. 10, 2015, pp. 1449-61.
Athyros VG, Katsiki N, Karagiannis A, et al. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother. 2015;16(10):1449-61.
Athyros, V. G., Katsiki, N., Karagiannis, A., & Mikhailidis, D. P. (2015). Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opinion On Pharmacotherapy, 16(10), 1449-61. https://doi.org/10.1517/14656566.2015.1053464
Athyros VG, et al. Statins Can Improve Proteinuria and Glomerular Filtration Rate Loss in Chronic Kidney Disease Patients, Further Reducing Cardiovascular Risk. Fact or Fiction. Expert Opin Pharmacother. 2015;16(10):1449-61. PubMed PMID: 26037614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? AU - Athyros,Vasilios G, AU - Katsiki,Niki, AU - Karagiannis,Asterios, AU - Mikhailidis,Dimitri P, Y1 - 2015/06/03/ PY - 2015/6/4/entrez PY - 2015/6/4/pubmed PY - 2015/12/15/medline KW - cardiovascular disease KW - chronic kidney disease KW - event rates KW - glomerular filtration rate KW - microalbuminuria KW - proteinuria KW - statins SP - 1449 EP - 61 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 16 IS - 10 N2 - INTRODUCTION: The prevalence of chronic kidney disease (CKD), a risk factor for cardiovascular disease (CVD), is increasing worldwide. Statin treatment, the cornerstone of prevention or treatment of CVD, might have beneficial effects on urine protein excretion and renal function as determined by the glomerular filtration rate, whereas it might protect from acute kidney injury (AKI), mainly due to contrast-induced AKI. These beneficial effects on CKD may not be drug class effects; specific statins at specific doses may help prevent CKD deterioration and reduce CVD risk. We analysed all statin studies that had renal and CVD endpoints as main outcome measures. MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched up to February 2015. AREAS COVERED: We consider the effects of statins on microalbuminuria, proteinuria, glomerular filtration rate, AKI associated with angiography or percutaneous coronary intervention and on CVD event rates in patients with CKD. EXPERT OPINION: Current evidence points towards the need to prescribe high-potency statins in patients with CKD, before a major decline in kidney function occurs. This may reduce CVD risk and delay the progress of CKD. Administration of either atorvastatin or rosuvastatin can prevent contrast-induced AKI before angiography or percutaneous coronary intervention. The combination of simvastatin + ezetimibe may decrease vascular events in patients with advanced CKD. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/26037614/Statins_can_improve_proteinuria_and_glomerular_filtration_rate_loss_in_chronic_kidney_disease_patients_further_reducing_cardiovascular_risk__Fact_or_fiction DB - PRIME DP - Unbound Medicine ER -